Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
1.
Tuberculosis and Respiratory Diseases ; : 256-259, 2013.
Artículo en Inglés | WPRIM | ID: wpr-194718

RESUMEN

Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, which can frequently occur due to the underlying disease. The standard treatment for imatinib-induced pneumonitis is to discontinue the medication and optionally administer corticosteroids. However, there are a few cases of successful retrial with imatinib. We describe a case of successful rechallenge of imatinib in a patient with imatinib-induced interstitial pneumonitis and CML without a recurrence of the underlying disease after 3 months of follow-up.


Asunto(s)
Humanos , Corticoesteroides , Estudios de Seguimiento , Tumores del Estroma Gastrointestinal , Leucemia Mielógena Crónica BCR-ABL Positiva , Enfermedades Pulmonares Intersticiales , Mesilatos , Neumonía , Proteínas Tirosina Quinasas , Recurrencia , Mesilato de Imatinib
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA